Sign in Subscribe
Pediatrics

Prednisone Response in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Study

Strategic Insights

— 1 min read

Current study results on pediatric acute lymphoblastic leukemia (ALL) have been published, focusing on the prognostic value of prednisone response. The study, conducted by investigators at the First Affiliated Hospital of Guangxi Medical University, analyzed clinical data from 2,979 pediatric patients primarily diagnosed with ALL. The results showed that prednisone response (PR) remained a key early treatment indicator but had waned in prognostic significance with the advent of minimal residual disease (MRD)-guided risk assessment.

Key Takeaways:

  • The study included 2,979 pediatric patients primarily diagnosed with ALL, with 2,649 categorized as "good prednisone response" (GPR) and 330 as "poor prednisone response" (PPR).
  • Children in the PPR group exhibited multiple high-risk clinical features and had a poorer prognosis than those in the GPR group.
  • Multivariate Cox regression analysis revealed that days 15 and 33 MRD had a stronger predictive value than prednisone response.
  • Prednisone response showed strong predictive value for MRD positivity on both Day 15 and Day 33.
  • The findings support the contextual use of PR as a practical surrogate for MRD in resource-limited settings and highlight the need to reconsider its role in modern risk-adapted treatment strategies.
  • Authors include Yun-Yan He, Jia-Tong Dai, Ya-Ting Zhang, Ya-Jie Zhang, Wu-Qing Wan, Wen-Guang Jia, Ming Cheng, Ying Liu, Yan-Lai Tang, Hui-Rong Mai, Shi-Lin Liu, Li-Li Liu, Ye-Sheng Ling, Qi-Wen Chen, Xing-Jiang Long, Liu-Hua Liao, Zi-Jun Zhen, Jian-Ling Cai and Qiao-Ru Li.

Statistics:

  • 2,979 pediatric patients were included in the study.
  • 2,649 patients were categorized as "good prednisone response" (GPR) and 330 as "poor prednisone response" (PPR).
  • Children in the PPR group had a poorer prognosis than those in the GPR group.
  • Days 15 and 33 MRD had a stronger predictive value than prednisone response in multivariate Cox regression analysis.

Sources:

  • A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia. Annals of Hematology, 2025.
  • Investigators at First Affiliated Hospital of Guangxi Medical University Target Acute Lymphoblastic Leukemia (A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia). Hematology Week. October 20, 2025; p 216.

Read more